Syngene International, Torrent Pharma, Laurus Labs And Other Healthcare Stocks Stand Tall on Monday as Iran War Rattles Dalal Street

Mumbai, May 11: Monday turned turbulent for Indian equity markets as US President Donald Trump publicly rejected Iran’s response to Washington’s peace proposal, dashing hopes of a swift resolution to the West Asia conflict. Benchmark indices bore the brunt of the geopolitical shock but one corner of the market held firm. The Nifty Healthcare Index traded up 0.65%, clocking 15,517 points even as broader indices bled, a quiet but powerful signal of the sector’s resilience in times of crisis.

Seven Stocks from the Index Told this Story Compellingly

Syngene International led the pack with a sharp gain of 5.82%, followed closely by Torrent Pharmaceuticals, which rose 3.54%, and Laurus Labs, which climbed 3.48%. Biocon added 3.25%, while Abbott India gained 3.03%. Sun Pharmaceutical and Max Healthcare rounded off the gainers, rising 1.50% and 2.42% respectively each moving higher while most sectoral indices struggled to stay in the green.

Why is Healthcare Outperforming when Global Markets are Rattled? 

The answer lies in a set of structural and situational advantages that make this sector the natural refuge in stormy weather.

First and foremost, healthcare is a classic defensive play. Demand for medicines, diagnostics, and hospital services does not dry up during wars or recessions. Investors instinctively rotate out of cyclical names banks, metals, real estate and into healthcare when geopolitical risk spikes, as it has today.

Second, the falling rupee is a direct tailwind for pharma exporters. With USD/INR hovering near the 95 level, Indian pharma companies that earn in dollars and report in rupees see an automatic boost to their top lines. Companies like Syngene, Laurus Labs, and Sun Pharma, which have significant US and global export exposure, benefit disproportionately from this currency dynamic.

Third, India’s position as the world’s pharmacy has never been more relevant. With global supply chains disrupted by the Strait of Hormuz crisis and rising freight costs, international buyers especially in the US, which sources the bulk of its generic drugs from India are doubling down on Indian pharma as a dependable supplier. This reinforces long-term order visibility for the sector.

Fourth, healthcare has zero direct exposure to crude oil prices. Unlike aviation, logistics, or paints, hospital chains and drug makers are insulated from the $105-per-barrel Brent crude shock that is squeezing margins elsewhere.

Finally, healthcare earnings are structurally improving. The sector has consistently delivered strong quarterly results, and with government spending on public health rising, domestic demand remains a steady base regardless of what happens beyond India’s borders.

In a Monday where Trump’s hardline stance on Iran reminded markets that peace remains distant, healthcare stocks quietly reminded investors of something equally important that in uncertainty, some sectors simply don’t blink.

Source:

• https://www.nseindia.com/market-data/live-equity-market?symbol=NIFTY%20HEALTHCARE%20INDEX
• NSE · Nifty Healthcare Index · 11 May 2026